Please login to the form below

Not currently logged in
Email:
Password:

Licensing deals

This page shows the latest Licensing deals news and features for those working in and with pharma, biotech and healthcare.

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead. ... The takeover is the latest in a string of big billion dollar-plus licensing and acquisition deals signed by Gilead since the start of 2019 under new chief executive Daniel

Latest news

More from news
Approximately 2 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    returns. That includes an exit from areas like neurology – which predates Bourla’s appointment as CEO but was set up while he was COO – and a series of bolt-on deals ... Meanwhile, Galapagos looks set to continue adding to its pipeline through

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    Furthermore, increases. in region or market-specific licensing deals for launch products have led companies to devolve to region-specific cross-functional teams for tailored launch preparation, allowing different thinking to

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    Mega-mergers are also becoming less frequent; instead, we’re seeing fewer but larger deals. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually decline while the

  • Deal Watch October 2018

    Licensing &. research. collaboration. $550m. Novartis/. Mylan. TOBI Podhaler and TOBI solution for cystic fibrosis. ... Licensing &. collaboration. $40m. All deals are for worldwide rights unless stated otherwise:.

  • Pharma deals continue to slide Pharma deals continue to slide

    Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... Licensing  . The most common licensing deal is big pharma licensing in from biotech.

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics